Ai Mediq S.A.

19, Rue de Bitbourg, 1273 Luxembourg
Luxembourg
Telephone +352 671 882215
info@aimediq.com
http://www.aimediq.com

Product Categories

Product categories

01 Electromedical Equipment / Medical Technology
01.06 Intense medicine / anesthesiology / respiration
01.06.02 Respiration equipment, oxygen equipment

Respiration equipment, oxygen equipment

Reoxy

04 Physiotherapy / Orthopaedic Technology
04.08 Physiotherapy equipment

Physiotherapy equipment
Our products

Product category: Respiration equipment, oxygen equipment
Reoxy
The operational safety of the unit is only assured when used for the purpose it is intended for, as specified in the instructions for use.
The ReOxy device must only be used according to the medical indication and only in accordance with the doctor’s prescription by following instructions for use.
The intended use also includes the compliance with the assembly instructions, as well as the notes on cleaning and maintenance of the ReOxy device.
Any other use of the unit beyond these limits is prohibited and is not considered as unintended use! Claims of any kind against the manufacturer and/or his authorized representatives resulting from damage caused by unintended use of the unit are excluded. The operator is solely liable for any damage resulting from unintended use.

ad: contact information

About Us

Company details
Ai Mediq is a Luxembourg-based ground-breaking medical technology company that develops novel non-invasive therapeutic solutions leveraging positive treatment effects of high altitude (hypoxic) exposure, medical devices for Intermittent Hypoxic Treatment, and medical software algorithms for its personalisation.

Ai Mediq is the first company in the world which commercialised the idea of using physiological effects of adaptation to short term episodes of hypoxia for clinical treatment purposes.

In 2014, the company has developed a medical device called ReOxy® for provision of an innovative breathing therapy method: Intermittent Hypoxic Hyperoxic Treatments (IHHT) with a biological feedback SRT® (Self-Regulated Treatment) technology.
Following successful commercialisation of the initial ReOxy version, Ai Mediq is now focused on adaptation and optimisation of the ReOxy device to novel markets with significant potential benefits for patients, customers and healthcare systems alike.

Company R&D Activities as a Private Sector Research Organization
Since 2013 Ai Mediq has focused its efforts on:

Research for the objectives:
– to scientifically evaluate influence of short-term, individually dosed, physiological feedback-controlled hypoxic exposure in healthy subjects and patients with different diseases (basic research)
– to evaluate efficacy of IHHT in rehabilitation of patients with cardiovascular, cerebrovascular and metabolic disorders</li.
Feasibility studies for the objectives:
– to validate efficacy and performance level of the IHHT/ SRT method intended for in- and outpatient markets over conventional supervised exercise-based cardiac rehabilitation methods.
Development of new innovative medical devices/their Prototyping (Industrial Research/Industrial Development)

ad: company

VistaMed Ltd.
SciPharm Sàrl
Advanced Biological Laboratories (ABL) S.A.
ARSPECTRA S.à.r.l.
DuPont de Nemours (Luxembourg) S.a.r.l.
ExoAtlet Global S.A.
Advanced Biological Laboratories (ABL) S.A.
SciPharm Sàrl
VistaMed Ltd.
Trulife Ltd.
TE Connectivity Ltd.

ARSPECTRA S.à.r.l.
DuPont de Nemours (Luxembourg) S.a.r.l.
ExoAtlet Global S.A.
Fast Track Diagnostics SARL
IEE S.A.